# Belite Bio, Inc American Depositary Shares (BLTE)

> Belite Bio, Inc American Depositary Shares (BLTE) trades at $154.74 (+2.97%) as of 7:30:02 PM EDT on Oct 30, 2026, -5.06% over the past month. Market cap is $6.23B, with 7.1 days to cover in short interest.

Canonical: https://massive.com/quote/blte
Data as of: 2026-10-30T23:30:02.209Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$154.74** +4.46 (+2.97%)
As of 7:30:02 PM EDT on Oct 30, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Belite Bio, Inc American Depositary Shares (BLTE) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.97% |
| 1W | +5.03% |
| 1M | -5.06% |
| YTD | -3.26% |
| 1Y | +37.67% |
| 52-wk range | $102.00 – $200.00 |

From daily closes through Oct 30, 2026.

## Key statistics

Today's trading snapshot for BLTE: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $146.90 – $156.33 |
| Open | $148.79 |
| Prev close | $150.28 |
| Volume | 234.88K |
| Market cap | $6.23B |
| Shares out | 40.27M |

## Insider trading

[Belite Bio, Inc American Depositary Shares (BLTE) insider trading](https://massive.com/quote/blte/insider-trading.md): open-market Form 4 buys and sells by Belite Bio, Inc American Depositary Shares insiders over the last 12 months.

## BLTE short interest

How heavily BLTE is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.1 |
| Short interest | 1.27M |
| Avg volume | 178.36K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## BLTE news

The latest news and headlines about Belite Bio, Inc American Depositary Shares (BLTE).

- [Belite Bio Announces Uplisting to the Nasdaq Global Select Market](https://www.globenewswire.com/news-release/2026/10/19/3383134/0/en/belite-bio-announces-uplisting-to-the-nasdaq-global-select-market.html) · GlobeNewswire Inc. · Oct 19, 2026 · positive sentiment
- [Belite Bio to Host Virtual Commercial Day on September 2, 2026](https://www.globenewswire.com/news-release/2026/08/24/3350087/0/en/belite-bio-to-host-virtual-commercial-day-on-september-2-2026.html) · GlobeNewswire Inc. · Aug 24, 2026 · positive sentiment
- [Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium](https://www.globenewswire.com/news-release/2026/07/06/3322356/0/en/Belite-Bio-to-Participate-in-the-Piper-Sandler-Virtual-Ophthalmology-Investor-Symposium.html) · GlobeNewswire Inc. · Jul 6, 2026 · positive sentiment
- [Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1](https://www.globenewswire.com/news-release/2026/06/13/3311366/0/en/Belite-Bio-Completes-Rolling-Submission-of-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-Tinlarebant-for-the-Treatment-of-Stargardt-Disease-Type-1.html) · GlobeNewswire Inc. · Jun 12, 2026 · positive sentiment
- [Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update](https://www.globenewswire.com/news-release/2026/05/20/3298259/0/en/Belite-Bio-Reports-Unaudited-First-Quarter-2026-Financial-Results-and-Provides-a-Corporate-Update.html) · GlobeNewswire Inc. · May 20, 2026 · positive sentiment

## About Belite Bio, Inc American Depositary Shares

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | ADRC |
| Currency | USD |
| Employees | 41 |
| Listed | Apr 29, 2022 |

[Company website](https://www.belitebio.com)

## FAQ

### What is the Belite Bio, Inc American Depositary Shares (BLTE) stock price today?

Belite Bio, Inc American Depositary Shares (BLTE) is trading at $154.74 (+2.97% on the day) as of 7:30:02 PM EDT on Oct 30, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Belite Bio, Inc American Depositary Shares?

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular…

### What is the short interest in BLTE?

As of Oct 15, 2026, BLTE has 1.27M shares short and 7.1 days to cover.

### What exchange is BLTE listed on?

Belite Bio, Inc American Depositary Shares (BLTE) trades on Nasdaq in USD.

## Live data

Prices here are 15-minute delayed. For real-time BLTE quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=BLTE`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Belite Bio, Inc American Depositary Shares (BLTE) insider trading](https://massive.com/quote/blte/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms